October 30, 2008
Acute Radiation Drug Treatment is Studied
A U.S. company says it's started initial human safety testing of a drug designed to treat exposure to radiation from nuclear weapons or a nuclear accident.
Cleveland BioLabs Inc. said it dosed its first healthy volunteer this month in the human safety study required by the U.S. Food and Drug Administration for the drug Protectan CBLB502.
Officials said the study is expected to take about six months to complete and will be followed by a second, larger safety study in healthy human volunteers.
Cleveland BioLabs received funding contracts totaling $22.2 million from federal agencies for development of the radiation countermeasure.
The company has strategic partnerships with the Armed Forces Radiobiology Research Institute, the Cleveland Clinic, Roswell Park Cancer Institute and the ChemBridge Corp.